|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for SCARB2 |
 Gene summary |
| Basic gene Info. | Gene symbol | SCARB2 |
| Gene name | scavenger receptor class B, member 2 | |
| Synonyms | AMRF|CD36L2|EPM4|HLGP85|LGP85|LIMP-2|LIMPII|SR-BII | |
| Cytomap | UCSC genome browser: 4q21.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001204255.1, NM_005506.3, | |
| Description | 85 kDa lysosomal membrane sialoglycoprotein85 kDa lysosomal sialoglycoprotein scavenger receptor class B, member 2CD36 antigen (collagen type I receptor, thrombospondin receptor)-like 2 (lysosomal integral membrane protein II)CD36 antigen-like 2LIMP I | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 602257 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000138760 | ||
| HPRD : 03772 | ||
| Vega : OTTHUMG00000130099 | ||
| Protein | UniProt: Q14108 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_SCARB2 | |
| BioGPS: 950 | ||
| Pathway | NCI Pathway Interaction Database: SCARB2 | |
| KEGG: SCARB2 | ||
| REACTOME: SCARB2 | ||
| Pathway Commons: SCARB2 | ||
| Context | iHOP: SCARB2 | |
| ligand binding site mutation search in PubMed: SCARB2 | ||
| UCL Cancer Institute: SCARB2 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for SCARB2 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | I155 | E157K | BLCA | 1 | I155 | I156M | BRCA | 1 | R153 | R153M | KIRC | 1 | I155 | E157K | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for SCARB2 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | I155 | E157K | -0.72398667 | R153 | R153M | -0.63131965 | I155 | I156M | -0.52514583 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for SCARB2 from PDB |
| Top |
| Differential gene expression and gene-gene network for SCARB2 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for SCARB2 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0751779 | EPILEPSY, PROGRESSIVE MYOCLONIC 4, WITH OR WITHOUT RENAL FAILURE | 8 | Biomarker, GeneticVariation |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for SCARB2 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of SCARB2 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | M6D | BETA-D-MANNOSE 6-PHOSPHATE | 4q4f | A | R153 I155 |
| Top |
| Conservation information for LBS of SCARB2 |
| Multiple alignments for Q14108 in multiple species |
| LBS | AA sequence | # species | Species | E154 | VHFLREIIEAM | 1 | Homo sapiens | E154 | LTLLRELIEAM | 1 | Mus musculus | E154 | QPFLREIIEAM | 1 | Rattus norvegicus | I155 | HFLREIIEAML | 1 | Homo sapiens | I155 | TLLRELIEAML | 1 | Mus musculus | I155 | PFLREIIEAML | 1 | Rattus norvegicus | L152 | SQVHFLREIIE | 1 | Homo sapiens | L152 | AQLTLLRELIE | 1 | Mus musculus | L152 | AQQPFLREIIE | 1 | Rattus norvegicus | R153 | QVHFLREIIEA | 1 | Homo sapiens | R153 | QLTLLRELIEA | 1 | Mus musculus | R153 | QQPFLREIIEA | 1 | Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |